Exclusive Summary

• Levosimendan's original patent has expired, and generics are available in multiple markets, indicating low entry barriers and significant market opportunities.
• The global burden of acute heart failure and cardiogenic shock is substantial and increasing with an aging population, driving continuous demand for fast-acting, hemodynamically improving drugs.
• Levosimendan is recommended in guidelines for acute decompensated heart failure patients with low cardiac output and tissue hypoperfusion, establishing its high clinical value and clear therapeutic position.
• Compared to the original drug, our generic offers significant cost advantages, substantially reducing the financial burden on healthcare systems and patients, thus enhancing market competitiveness.
• Active pursuit of international quality certifications (e.g., cGMP) and strong international registration experience will provide a solid foundation for global market access and sales.

Asset Materials

Contact Us for Full Materials